Cantor Fitzgerald Reiterates Overweight on UniQure, Maintains $24 Price Target

Cantor Fitzgerald analyst Kristen Kluska reiterates uniQure (NASDAQ:QURE) with a Overweight and maintains $24 price target.

BenzingaJul 16 09:13 ET

UniQure Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/16/2024 158.74% Cantor Fitzgerald $24 → $24 Reiterates Overweight → Overweight 07/09/2024 169.52% HC

BenzingaJul 16 09:12 ET

UniQure (NASDAQ:QURE) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you

Simply Wall StJul 12 09:03 ET

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below

BenzingaJul 11 14:02 ET

William Blair Maintains UniQure NV(QURE.US) With Buy Rating

William Blair analyst Sami Corwin maintains $uniQure NV(QURE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 39.8% and a total average return of -1.2% over the

Moomoo NewsJul 11 06:31 ET · Ratings

Why Are UniQure Shares Surging Today?

UniQure N.V. (NASDAQ:QURE) shares are skyrocketing Wednesday following the release of promising interim data from its Phase I/II clinical trials of AMT-130, a gene therapy targeting Huntington's disease.

BenzingaJul 10 16:00 ET